Edition:
India

Pernix Therapeutics Holdings Inc (PTX.OQ)

PTX.OQ on NASDAQ Stock Exchange Global Market

1.14USD
2:29am IST
Change (% chg)

$-0.47 (-29.19%)
Prev Close
$1.61
Open
$1.60
Day's High
$1.60
Day's Low
$1.13
Volume
522,891
Avg. Vol
131,380
52-wk High
$3.30
52-wk Low
$0.27

Latest Key Developments (Source: Significant Developments)

Pernix Therapeutics Received Feedback From FDA About Supplemental Application Related To Zohydro
Thursday, 22 Nov 2018 

Nov 21 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS - RECEIVED FEEDBACK FROM FDA ABOUT SUPPLEMENTAL APPLICATION RELATED TO ZOHYDRO.PERNIX THERAPEUTICS HOLDINGS - FDA DETERMINED THAT IT WILL CONSIDER ZOHYDRO SUBMISSION TO BE A "PRIOR APPROVAL SUPPLEMENT" - SEC FILING.PERNIX THERAPEUTICS - BELIEVES DUE TO EXPECTED REVIEW CYCLE FOR PAS, 20 MG. STRENGTH CAPSULE OF ZOHYDRO WILL BE ON BACK ORDER UNTIL AT LEAST Q2 2019.PERNIX THERAPEUTICS HOLDINGS INC - ANTICIPATES THAT STOCKOUT OF 20 MG. STRENGTH CAPSULES WILL IMPACT OVERALL ZOHYDRO PRESCRIPTION VOLUME.PERNIX THERAPEUTICS-AFTER EVALUATING SCOPE OF POTENTIAL FINANCIAL IMPACT, CO DOES NOT BELIEVE THAT STOCKOUT WILL HAVE MATERIAL FINANCIAL IMPACT ON CO.PERNIX THERAPEUTICS - PROPOSES TO ADDRESS SUPPLIER'S DISCLOSED MANUFACTURING ISSUE AND RELATES TO QUANTITATIVE FORMULATION OF INACTIVE INGREDIENT.  Full Article

Pernix Therapeutics Holdings Q3 Loss Per Share $0.89
Friday, 9 Nov 2018 

Pernix Therapeutics Holdings Inc ::PERNIX® THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.89.Q3 REVENUE FELL 8 PERCENT TO $37.2 MILLION.  Full Article

Pernix Therapeutics Says Angus Smith To Resign As Principal Financial Officer
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS SAYS ANGUS SMITH TO RESIGN AS PRINCIPAL FINANCIAL OFFICER - SEC FILING.PERNIX THERAPEUTICS - NAMED GLENN WHALEY AS PRINCIPAL FINANCIAL OFFICER.  Full Article

Pernix No Longer Meets Nasdaq Requirement Of Minimum Market Value Of Publicly Held Shares
Tuesday, 23 Oct 2018 

Oct 22 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS - ON OCT 17 RECEIVED LETTER FROM NASDAQ THAT IT NO LONGER MEETS REQUIREMENT OF MINIMUM MARKET VALUE OF PUBLICLY HELD SHARES.  Full Article

Pernix Therapeutics Holdings’S Subsidiaries File Notice Of Appeal
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS HOLDINGS, INC.’S SUBSIDIARIES FILE NOTICE OF APPEAL IN PATENT LITIGATION CONCERNING ZOHYDRO® ER WITH BEADTEK®.PERNIX THERAPEUTICS - DECISION HAS NO IMMEDIATE IMPACT ON CO'S JAN 2018 SETTLEMENT WITH ACTAVIS ON PROPOSED GENERIC VERSION OF ZOHYDRO ER WITH BEADTEK.PERNIX THERAPEUTICS HOLDINGS INC - COURT FOUND ASSERTED CLAIMS OF U.S. PATENT TO BE INFRINGED, BUT INVALID.  Full Article

Agrofresh Names Graham Miao As New CFO
Friday, 31 Aug 2018 

Aug 30 (Reuters) - AgroFresh Solutions Inc ::AGROFRESH ANNOUNCES CFO CHANGE; NAMES GRAHAM MIAO AS NEW CFO.AGROFRESH SOLUTIONS INC - GRAHAM MIAO WILL BE REPLACING KATHERINE HARPER.AGROFRESH SOLUTIONS INC - MOST RECENTLY, MIAO WAS PRESIDENT AND CFO OF PERNIX THERAPEUTICS HOLDINGS.  Full Article

Pernix Therapeutics Announces Ruling In Patent Litigation
Monday, 27 Aug 2018 

Aug 27 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS ANNOUNCES RULING IN PATENT LITIGATION CONCERNING ZOHYDRO ER WITH BEADTEK.PERNIX THERAPEUTICS - IN CO'S LITIGATION AGAINST ALVOGEN MALTA OPERATIONS, COURT FOUND ASSERTED CLAIMS OF U.S. PATENTS TO BE INFRINGED, BUT INVALID.PERNIX THERAPEUTICS - LITIGATION RELATES TO ALVOGEN'S SUBMISSION OF ANDA TO FDA FOR APPROVAL TO MARKET GENERIC VERSION OF CO'S ZOHYDRO ER WITH BEADTEK.PERNIX THERAPEUTICS HOLDINGS INC - INTENDS TO APPEAL INVALIDITY RULING ASPECT OF COURT'S DECISION.  Full Article

Pernix Therapeutics Announces A Series Of Transactions To Strengthen Its Balance Sheet And Improve Financial Flexibility
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS ANNOUNCES A SERIES OF TRANSACTIONS TO STRENGTHEN ITS BALANCE SHEET AND IMPROVE FINANCIAL FLEXIBILITY.PERNIX THERAPEUTICS - ENTERED INTO EXCHANGE AGREEMENTS WITH CERTAIN HOLDERS OF PERNIX'S OUTSTANDING 12% SENIOR SECURED NOTES DUE 2020.PERNIX THERAPEUTICS - ALSO ENTERED AMENDMENT TO DELAYED DRAW TERM LOAN FACILITY AMONG A WHOLLY OWNED SUBSIDIARY OF PERNIX AND LENDERS.PERNIX THERAPEUTICS HOLDINGS INC - ALSO ENTERED INTO AMENDMENTS TO ASSET-BASED REVOLVING CREDIT FACILITY AGREEMENT.PERNIX THERAPEUTICS - AMENDMENTS WERE MADE TO PERMIT EXCHANGE OF SENIOR SECURED NOTES INTO COMMON STOCK IN EXCHANGE TRANSACTIONS.PERNIX THERAPEUTICS - AMENDMENTS INCLUDES REDUCTION IN COMMITMENTS UNDER ABL FACILITY FROM $40.0 MILLION TO $32.5 MILLION.  Full Article

Pernix Therapeutics Reports Result Of Bid Process For Acquisition Of Worldwide Rights To Contrave
Friday, 22 Jun 2018 

June 22 (Reuters) - Pernix Therapeutics Holdings Inc ::PERNIX THERAPEUTICS ANNOUNCES RESULT OF BID PROCESS FOR ACQUISITION OF WORLDWIDE RIGHTS TO CONTRAVE® FOR WEIGHT LOSS.NALPROPION PHARMACEUTICALS INFORMED BY OREXIGEN THERAPEUTICS NO OTHER BIDS FOR OREXIGEN'S ASSETS GOT BY COURT-APPROVED BID DEADLINE.NALPROPION ANTICIPATES BEING DECLARED HIGHEST, BEST BIDDER FOR ASSETS AND CLOSING ON DEAL BY JULY 13, 2018.  Full Article

Orexigen Therapeutics Enters Agreement For Sale Of Co
Monday, 23 Apr 2018 

April 23 (Reuters) - Orexigen Therapeutics Inc ::OREXIGEN THERAPEUTICS, INC. ENTERS AGREEMENT FOR SALE OF COMPANY.OREXIGEN THERAPEUTICS INC - ENTERED INTO ASSET PURCHASE DEAL WITH NALPROPION PHARMACEUTICALS, TO SELL SUBSTANTIALLY ALL OF ASSETS OF CO.OREXIGEN THERAPEUTICS INC - WILL SELL WORLD-WIDE RIGHTS TO CONTRAVE /MYSIMBA AND CERTAIN OTHER OREXIGEN ASSETS FOR $75 MILLION IN CASH.OREXIGEN THERAPEUTICS- NALPROPION PHARMACEUTICALS IS A NEWLY FORMED SPECIAL PURPOSE ENTITY CAPITALIZED BY INVESTOR GROUP INCLUDING PERNIX THERAPEUTICS.  Full Article